Companies
IBBIS
launched May 2024 as a free, open-source synthesis-screening package more robust against evasion attempts — including AI-generated sequences — than basic sequence-matching approaches, spun out of a US biosecurity nonprofit into an independent Swiss foundation.
- Country
- Switzerland
open-source
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfda
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Affiliation | Incubated by the Nuclear Threat Initiative (NTI) | bio | ibbis.bio · longtermwiki.com |
| Research focus | DNA synthesis screening, biosecurity norms, and reducing emerging biological risks | ibbis.bio · longtermwiki.com |
| Headquarters | Geneva, Switzerland | ibbis.bio · longtermwiki.com |
| Grant | $3 million launch grant from Founders Pledge | longtermwiki.com |
| Principal staff | Piers Millett (Executive Director), Tessa Alexanian (Technical Lead), Rassin Lababidi (Technical Lead), Sophie Peresson (Technical Lead) | longtermwiki.com |
| Publications | Common Mechanism (commec) software package, various technical white papers and articles on biosecurity screening | ibbis.bio |
Independent sources: longtermwiki.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| DNA synthesis biosecurity screening | genome-engineering | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.